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ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section EditorInhibition of annexin V binding to cardiolipin and thrombin genera-
tion in an unselected population with venous thrombosis
Hanly JG, Smith SA, Anderson D. J Rheumatol 2003;30:190-3.
Conclusion: Abnormalities in annexin V may contribute to the pro-
coagulant state in patients with idiopathic venous thrombosis.
Summary: The authors evaluated 111 patients who came to an
emergency room with symptoms suggestive of venous thromboembolism
(VTE). In 34 patients the diagnosis of lower extremity deep venous
thrombosis or pulmonary embolism was confirmed (VTE-positive
group). Seventy-seven patients with normal findings at diagnostic
workup for VTE composed the control group (VTE-negative group).
Plasma samples were collected before beginning anticoagulation, and
were examined for immunoglobulin G (IgG) anti-cardiolipin, IgG anti-
2-glycoprotein1, and IgG anti-prothrombin antibodies with an enzyme-
linked immunosorbent assay. They also examined the effect of individual
patient variables on control plasma samples of annexin V binding to
anti-cardiolipin and on in vitro thrombin generation determined with a
competitive enzyme-linked immunosorbent assay and a chromogenic
assay.
Prevalence and levels of IgG anti-cardiolipin, anti-2-glycoprotein 1,
and anti-prothrombin antibodies were similar in the groups with and with-
out VTE. Plasma samples from the VTE-positive group, however, caused a
significant inhibition of in vitro thrombin generation, and concurrent, less
impressive inhibition of annexin V binding to aCL. Only age and inhibition
of thrombin generation were significantly associated with VTE.
Comment: Despite improvement in detection of hypercoagulable
states, many patients with unprovoked VTE have, as yet, no identifiable
hypercoagulable abnormality. The study suggests that annexin V abnormal-
ities may result in a minor hypercoagulable state. It is still unclear whether
annexin V abnormalities can act in isolation to produce VTE.
A prospective registry of carotid angioplastine and stenting
Theiss W, Hermanek P, Mathias K, et al. Radiology 2004;35:2134-9.
Conclusion: Carotid angioplasty and stenting (CAS) may be per-
formedwith similar results in the community setting, as has been reported by
highly specialized centers and in clinical studies.
Summary: The German Societies of Angiology and Radiology insti-
tuted a prospective registry of CAS to limit its uncontrolled use and collect
data about technique and results of CAS outside of clinical trials. The
registry is open to investigators in Germany, Austria, and Switzerland who
are active in CAS. Thirty-eight centers participate. Patients are prospectively
interviewed before CAS is performed. At discharge from the hospital,
technical details, periprocedural medications, and clinical course are re-
ported on a standardized form.
After 4 years, 3853 planned interventions were recorded in the registry.
CASwas attempted in 3267 patients. Of these, 56% had symptomatic disease
and 44% had asymptomatic disease. In 98% of patients stents were used, 89%
of which were self-expanding. Other technical aspects of CAS, including
cerebral protection devices and methods of periprocedural monitoring,
varied widely among centers. Periprocedural medications generally included
aspirin and clopidogrel before and after CAS, and high-dose heparin and
atropine during CAS. CAS was technically successful in 3207 patients (98%).
In-hospital mortality was 0.6% (n  18). In-hospital major stroke rate was
1.2% (n  38), and in-hospital minor stroke rate was 1.3% (n  41).
Combined stroke and death rate was 2.8% (n  90).
Comment: There are ongoing trials to evaluate the efficacy of CAS
versus carotid endarterectomy. These trials will determine the relative utility
of the 2 procedures. In the meantime, studies such as this one can be used to
justify randomized trials of carotid endarterectomy versus CAS. Because of
the limitations of a registry format, and the very short-term follow up
(in-hospital only) of registry patients, this trial should not, and cannot, be
used to justify performance of CAS in the community setting.
Elevated plasma factor VIII and D-dimer levels as predictors of poor
outcome of thrombosis in children
Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ, and Mountain
States Regional Thrombophilia Group. N Engl J Med 2004;351:1081-8.
Conclusion: Elevated levels of plasma factor VIII, D-dimer, or both at
diagnosis and during follow-up after the standard duration of anticoagula-
tion therapy predict poor outcomes in children with thrombosis.
176Summary: Elevated levels of plasma factor VIII and D-dimer predict
recurrent venous thromboembolism in adults (N Engl J Med 2000;343:
457-62; Thromb Haemost 2002;87:7-12). The authors investigated
whether elevated levels of factor VIII, D-dimer, or both at diagnosis, and
persistence of these laboratory abnormalities after anticoagulation therapy
correlated with poor outcome of thrombosis in children, defined as those
from birth to age 21 years. Data analyzed were from Children’s Hospital in
Denver and hospitals participating in the Mountain States Regional Hemo-
philia and Thrombosis Center. The study included 144 children with
radiologically confirmed acute thrombotic events. All initially received hep-
arin therapy, followed by warfarin sodium for 3 to 6 months. Follow-up was
at 3, 6, and 12months, and then annually. Repeat thrombophilia testing was
performed in children with previously abnormal factor VIII and D-dimer
levels.
Complete data were available for analysis in 82 children. Of these 82
children, 67% had factor VIII levels greater than 150 IU/dL, D-dimer
levels greater than 5 ng/mL, or both, at diagnosis. In the 75 patients in
whom thrombophilia testing was performed after 3 to 6 months of
anticoagulation therapy, 43% had persistent elevation of at least 1 of these
2 laboratory values at a median follow-up of 12 months (range, 3
months–5 years), and 51% of the 82 patients had a poor outcome, such as
lack of thrombus resolution, recurrent thrombosis, or postthrombotic
syndrome. Elevated levels of factor VIII, D-dimer, or both at diagnosis
predicted a poor outcome, with an odds ratio of 6.1 (P  .008).
Persistence of at least 1 laboratory abnormality at 3 to 6 months also
predicted poor outcome, with an odds ratio of 4.7 (P  .002). A
combination of factor VIII level greater than 150 IU/dL and D-dimer
level greater than 5 ng/mL at diagnosis was predictive of poor outcome,
with 91% specificity. After 3 to 6 months of standard anticoagulation this
combination predicted poor outcome with 88% specificity.
Comment: Children with thrombosis should not be considered just
small adults. Children have lower concentrations of physiologic inhibitors of
the coagulation system and a more limited fibrolytic capacity than adults do.
These differences in the coagulation systems between adults and children are
particularly prominent in the first year of life and at puberty and adolescence
(Thromb Haemost 1995;74:415-25). This study’s identification of specific
levels of factor VIII and D-dimer in children with thrombosis should help
guide anticoagulation therapy in children and, it is hoped, reduce the burden
of late thrombosis-related complications in pediatric patients.
N-acetylcysteine vs fenoldopan mesylate to prevent contrast agent–
associated nephrotoxicity
Birguori C, Colombo A, Airoldi F, et al. Am J Cardiol 2004;44:762-5.
Conclusion: N-acetylcysteine (NAC) is more effective then fenoldo-
pan in preventing contrast agent–induced nephrotoxicity.
Summary: Both fenoldopan mesylate, a specific antagonist of the
dopamine-1 receptor, and NAC are thought to prevent contrast agent–
associated nephrotoxicity. The authors randomly assigned 192 consecutive
patients with chronic renal insufficiency who were referred for coronary or
peripheral procedures involving administration of contrast agents to receive
intravenous hydration with 0.45% saline solution and NAC (1200 mg orally
twice daily) or fenoldopan (0.10 g/kg/min) before and after nonionic
iso-osmolar contrast dye administration. There were 97 patients in the NAC
group, and 95 patients in the fenoldopan group.
Creatinine concentration was similar in the 2 groups of patients. The
amount of contrast medium administered was similar in the 2 groups (P 
.54). An increase in creatinine concentration of at least 0.5 mg/dL 48 hours
after the procedure occurred in 4 of 97 patients (4.1%) in the NAC group
and in 13 of 95 patients (13.7%) in the fenoldopan group (P  .019; odds
ratio, 0.27; 95% confidence interval, 0.08-0.85).
Comment: Fenoldopan is thought to potentially selectively increase
blood flow to the renal medulla. The findings of this study, however,
indicate that fenoldopan is ineffective in preventing further deterioration in
renal function in patients with chronic renal insufficiency receiving an
iodinated contrast agent. On the basis of these data, and considering the
high cost of fenoldopan, hydration plus fenoldopan should not be used as
prophylaxis to prevent contrast agent–associated neuropathy.
Endoluminal stent-graft placement for acute rupture of the descending
thoracic aorta
Scheinert D, Krankenberg H, Schmidt A, et al. Eur Heart J 2004;25:694-
700.
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Volume 41, Number 1 Abstracts 177Conclusion: Stent-graft placement is an effective option for emergency
repair of descending thoracic aortic perforations.
Summary: The authors evaluated 31 consecutive patients who under-
went catheter-based treatment of perforating lesions of the descending
aorta. Twenty-one patients received treatment of rupture of a descending
thoracic aneurysm or descending thoracic aortic dissection, and 10 patients
received treatment of traumatic disruption of the descending aorta. A total
of 32 endographs were implanted.
Endograft placement was successful in all patients. In 1 patient a second
prosthesis was necessary, because of type I endoleak. Themortality rate at 30
days was 9.7%. One of 3 deaths occurred secondary to type I endoleak and
aortic rupture. All 3 deaths occurred in patients with rupture of a descending
thoracic aneurysm or thoracic dissection. Other complications associated
with placement of the endograft were also more common in patients who
received treatment of a descending thoracic aneurysm or dissection, com-
pared with those who received treatment of traumatic transection of the
descending aorta (28.6% vs 10%). The left subclavian artery was intentionally
covered in 6 patients, without amajor acute adverse event. No complications
were noted secondary to placement of endograft struts into the aortic arch.
There was no paraplegia and no further deaths or ruptures during a mean
follow-up of 17 months.
Comment: Clearly, endograft repair of thoracic aortic disruption is
feasible with excellent short-term results in selected patients. It is still unclear
the percent of patients with acute thoracic disruption who will be eligible for
endograft therapy. Nevertheless, as these devices become more available,
endograft therapy for acute thoracic aortic disruption will be the preferred
treatment in selected patients.
Randomized clinical trial of distal anastomotic interposition vein cuff
and infrainguinal polytetrafluoroethylene (PTFE) bypass grafting
Griffiths GD, Nagy J, Black D, et al. Br J Surg 2004;91:560-2.
Conclusion: Three-year patency rates for femoral to below-knee pop-
liteal polytetrafluoroethylene (PTFE) bypasses are improved with use of a
Miller cuff. Miller cuffs have no effect on patency rates for femoral to
above-knee popliteal bypasses at 5 years, and do not improve limb salvage in
either above-knee or below-knee PTFE bypasses.
Summary: The authors examined the effect of a Miller vein cuff at the
distal anastomosis of a PTFE graft on median to long-term patency of
femoral to above-knee and femoral to below-knee bypasses. Outcome
measures were bypass graft patency and limb salvage. This was a prospective,
randomized clinical trial with 261 bypass operations originally randomized.
Data were available for 235 bypasses (120 with a Miller cuff, 115 without).
Mean age of patients in the cuff group was 67.2 years, and in the non-cuff
group was 69.3 years (P  .72). The indication for operation was limb
salvage in 89% of each group. Cumulative 5-year patency for above-knee
bypasses with a Miller cuff was 40%, compared with 42% for the non-cuffed
bypasses (P  .702). Cumulative 3-year patency for below-knee bypasses
with aMiller cuff was 45%, compared with 19% for non-cuffed bypasses (P
.018). The Miller cuff had no significant effect on limb salvage for either
above-knee or below-knee bypasses.
Comment:When PTFE bypass is indicated to the below-knee popliteal
artery in a primarily limb salvage population, a Miller cuff should be used.
The results also suggest that PTFE bypass to the popliteal artery for limb
salvage, whether above or below the knee, has relatively poor long-term
patency.
Chronic kidney disease and the risks of death, cardiovascular events,
and hospitalization
Go AS, Chertow GM, Fan D, et al. N Engl J Med 2004;351:1296-1305.Conclusion: Progressive levels of renal insufficiency substantially in-
crease the risk for death or cardiovascular disease, and use of healthcare
resources. The effect is more marked with end-stage renal disease than with
milder levels of renal insufficiency.
Summary: The authors estimated longitudinal glomerular filtration
rate (GFR) in 1,120,295 adults in the Renal Registry of Kaiser Permanente
of Northern California. In patients in the registry, 1 or more outpatient
determinations of serum creatinine levels were made between January 1,
1996, and December 31, 2000. Excluded were patients with kidney trans-
plants and those receiving maintenance dialysis. Multivariable analysis was
used to examine the association between estimated GFR and the risk for
death, cardiovascular events, and hospitalization.
Median follow-up was 2.84 years. Mean patient age was 52 years; 55%
of patients were women. After adjustment, risk for death increased as GFR
decreased below 60 mL/min/1.73m2 of body surface area. The adjusted
hazard ratio for death was 1.2 with an estimated GFR of 45 to 59 mL/min/
1.73m2 (95% confidence interval [CI], 1.1-1.2), 1.8 with an estimated GFR
of 30 to 45mL/min/1.73m2 (95%CI, 1.7-1.9), 3.2 with an estimatedGFR
of 15 to 29 mL/min/1.71m2 (95% CI, 3.1-3.4), and 5.9 with an estimated
GFR less than 15mL/min/1.73m2 (95% CI, 5.4-6.5). Adjusted hazard
ratios for cardiovascular events also increased inversely with estimated GFR:
1.4 (95%CI, 1.4-1.5), 2.0 (95%CI, 1.9-2.1), 2.8 (95%CI, 2.6-2.9), and 3.4
(95% CI, 3.1-3.8), respectively. Risk for hospitalization also correlated with
reduced estimates of GFR.
Comment: Chronic renal disease, even when it does not necessitate
dialysis, has considerable adverse effects. While prevention of end-stage renal
disease is clearly important, more effective management of milder levels of
renal insufficiency is also needed to reduce the adverse health effects of lesser
levels of impaired renal function.
Below-knee elastic compression stockings to prevent the post-
thrombotic syndrome: A randomized, controlled trial
Prandoni P, Lensing AWA, Prins MH, et al. Ann Intern Med 2004;141:
249-56.
Conclusion: Below-knee elastic compression stockings reduce devel-
opment of postthrombotic syndrome in almost half of patients with proxi-
mal deep venous thrombosis (DVT).
Summary: The authors sought to evaluate the ability of elastic com-
pression stockings to prevent postthrombotic syndrome in patients with
acute proximal DVT. This randomized, controlled trial, conducted in a
university hospital in Italy, included 180 consecutive patients with a first
episode of symptomatic proximal DVT treated with conventional anticoag-
ulation therapy. Before discharge, patients were randomly assigned to use
below-knee elastic compression stockings (30-40 mmHg at the ankle) for 2
years. Follow-up extended up to 5 years. Presence and severity of postthrom-
botic syndrome was scored with a standardized scale.
Sequela of postthrombotic syndrome developed in 44 of 90 control
patients, and was severe in 10. Sequela of postthrombotic syndrome devel-
oped in 23 of 90 patients wearing elastic stockings, and was severe in 3. The
cumulative incidence of postthrombotic syndrome in the control group
versus the elastic stocking group was 40.0% (95% confidence interval [CI],
29.9-50.1) versus 21.1% (95% CI, 12.7-29.5) after 6 months, 46.7% (95%
CI, 36.4-57.0) versus 22.2% (95% CI, 13.8-30.7) after 1 year, and 49.1%
(95% CI, 38.7-59.4) versus 24.5% (95% CI, 15.6-33.4) after 2 years. The
hazard ratio for postthrombotic syndrome in the elastic compression stock-
ings group compared with the control group was 0.49 (CI, 0.29-0.84; P 
.011).
Comment: This study and a previous study by Brandjes et al (Lancet
1997;349:759-62) indicate a beneficial effect of prophylactic elastic com-
pression stockings in preventing postthrombotic syndrome in patients with
symptomatic proximal DVT. Patients with proximal DVT should use elastic
compression stockings to reduce the incidence of postthrombotic syndrome.
